These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

857 related articles for article (PubMed ID: 24323817)

  • 1. Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset.
    Collongues N; Marignier R; Jacob A; Leite MI; Siva A; Paul F; Zephir H; Akman-Demir G; Elsone L; Jarius S; Papeix C; Mutch K; Saip S; Wildemann B; Kitley J; Karabudak R; Aktas O; Kuscu D; Altintas A; Palace J; Confavreux C; De Seze J
    Mult Scler; 2014 Jul; 20(8):1086-94. PubMed ID: 24323817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
    Kitley J; Leite MI; Nakashima I; Waters P; McNeillis B; Brown R; Takai Y; Takahashi T; Misu T; Elsone L; Woodhall M; George J; Boggild M; Vincent A; Jacob A; Fujihara K; Palace J
    Brain; 2012 Jun; 135(Pt 6):1834-49. PubMed ID: 22577216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Late-onset neuromyelitis optica spectrum disorder in AQP4-seropositivepatients in a Chinese population.
    Mao Z; Yin J; Zhong X; Zhao Z; Qiu W; Lu Z; Hu X
    BMC Neurol; 2015 Sep; 15():160. PubMed ID: 26337073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
    Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J
    JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Characteristics of Chinese Male Patients with Aquaporin-4 Antibody-Positive Late-Onset Neuromyelitis Optica Spectrum Disorder.
    Liang J; Liu J; Gu M; Zhu C; Xu X; Fan R; Peng F; Jiang Y
    Neuroimmunomodulation; 2021; 28(2):61-67. PubMed ID: 33946074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea.
    Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH
    Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study.
    Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M
    Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder Patients in Turkish Cohort: Demographic, Clinical, and Laboratory Features.
    Altintas A; Karabudak R; Balci BP; Terzi M; Soysal A; Saip S; Tuncer Kurne A; Uygunoglu U; Nalbantoglu M; Gozubatik Celik G; Isik N; Celik Y; Gokcay F; Duman T; Boz C; Yucesan C; Mangan MS; Celebisoy N; Diker S; Colpak Isikay I; Kansu T; Siva A
    Neurologist; 2015 Oct; 20(4):61-6. PubMed ID: 26468870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
    Kim SM; Waters P; Woodhall M; Kim JY; Kim JE; Yang JW; Kim JS; Sung JJ; Park KS; Lee KW
    Mult Scler; 2013 Jul; 19(8):1060-7. PubMed ID: 23329699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical characteristics and follow-up of pediatric patients with neuromyelitis optica and neuromyelitis optica spectrum disorders].
    Yun W; Weihua Z; Xiaotun R; Jiuwei L; Xinying Y; Junlan L; Changhong D; Chunhong C; Haitao R; Liying C; Fang F
    Zhonghua Er Ke Za Zhi; 2015 Apr; 53(4):268-73. PubMed ID: 26182501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population.
    Papathanasiou A; Tanasescu R; Tench CR; Rocha MF; Bose S; Constantinescu CS; Jacob S
    J Neurol Sci; 2021 Dec; 431():120039. PubMed ID: 34715481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical spectrum of CNS aquaporin-4 autoimmunity.
    Kim SH; Kim W; Li XF; Jung IJ; Kim HJ
    Neurology; 2012 Apr; 78(15):1179-85. PubMed ID: 22459676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinctive characteristics of early-onset and late-onset neuromyelitis optica spectrum disorders.
    Zhang LJ; Yang LN; Li T; Wang J; Qi Y; Zhang DQ; Yang CS; Yang L
    Int J Neurosci; 2017 Apr; 127(4):334-338. PubMed ID: 27788616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies.
    Kitley J; Leite MI; Küker W; Quaghebeur G; George J; Waters P; Woodhall M; Vincent A; Palace J
    JAMA Neurol; 2013 Nov; 70(11):1375-81. PubMed ID: 23999580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models.
    Wang L; Du L; Li Q; Li F; Wang B; Zhao Y; Meng Q; Li W; Pan J; Xia J; Wu S; Yang J; Li H; Ma J; ZhangBao J; Huang W; Chang X; Tan H; Yu J; Zhou L; Lu C; Wang M; Dong Q; Lu J; Zhao C; Quan C
    Front Immunol; 2022; 13():873576. PubMed ID: 35432315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Features of anti-aquaporin 4 antibody-seropositive Chinese patients with neuromyelitis optica spectrum optic neuritis.
    Li H; Wang Y; Xu Q; Zhang A; Zhou H; Zhao S; Kang H; Peng C; Cao S; Wei S
    J Neurol; 2015 Oct; 262(10):2293-304. PubMed ID: 26162715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome and prognosis in patients with neuromyelitis optica spectrum disorder from Serbia.
    Drulovic J; Martinovic V; Basuroski ID; Mesaros S; Mader S; Weinshenker B; Pekmezovic T
    Mult Scler Relat Disord; 2019 Nov; 36():101413. PubMed ID: 31586803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.
    Wang L; Tan H; Huang W; Chang X; ZhangBao J; Zhou L; Lu C; Wang M; Lu J; Zhao C; Quan C
    Eur J Neurol; 2022 Apr; 29(4):1128-1135. PubMed ID: 34967093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.